Laigo Bio raises EUR11.5 million in seed financing to advance its SureTAC(TM) targeted protein degradation candidates in oncology and auto-immunity
Laigo Bio raises EUR11.5 million in seed financing to advance its SureTAC(TM) targeted protein degradation candidates in oncology and auto-immunity GlobeNewswire December 04, 2025 Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEO Laigo Bio's SureTAC(TM) membrane protein degradation technology targets key signaling molecules in […]